Securities Code: 300497 Securities Abbreviation: Fuxiang Shares Announcement No.: 2026-069
Jiangxi Fuxiang Pharmaceutical Co., Ltd.
Announcement on Diluted Earnings Per Share, Fill-in Measures, and Commitments of Relevant Parties Regarding the Private Placement of Shares in 2026
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or significant omissions.
Jiangxi Fuxiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Fuxiang Shares") held its tenth meeting of the Fifth Board of Directors on July 31, 2026, and approved the relevant proposals regarding the Company's private placement of A shares to specific objects. In accordance with the "Opinions of the General Office of the State Council on Further Strengthening the Protection of the Legitimate Rights and Interests of Small and Medium Investors in the Capital Market" (Guo Ban Fa [2013] No. 110), the "Several Opinions of the State Council on Further Promoting the Healthy Development of the Capital Market" (Guo Fa [2014] No. 17), and the "Guiding Opinions on Matters Concerning the Dilution of Immediate Returns from Initial Public Offerings, Refinancing, and Major Asset Restructurings" (CSRC Announcement [2015] No. 31), and other relevant laws, administrative regulations, and normative documents, in order to protect the interests of small and medium investors, the Company has conducted a thorough analysis of the impact of this private placement of A shares on immediate returns and proposed specific measures to fill in the returns, and the relevant parties have made commitments to ensure the effective implementation of the Company's measures to fill in the returns. The details are as follows:
I. Impact of this Private Placement on the Company's Main Financial Indicators
(I) Assumptions and Prerequisites for Financial Indicator Calculations
Based on the following assumptions, the Company analyzes the impact of this private placement on the Company's main financial indicators. Investors are specially reminded that these assumptions do not constitute any forecast or commitment, and investors should not make investment decisions based on them. The Company shall not bear any compensation liability for losses incurred by investors making investment decisions based on these assumptions. The actual situation of this private placement plan and its completion time will be subject to the approval and registration of the China Securities Regulatory Commission. The specific assumptions are as follows: